NCT02097225 2024-10-16
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
Clinical Trials
3 trialsNCT01940809 2022-03-10
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01907802 2018-08-14
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Terminated